Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details) - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Apr. 25, 2025 |
Apr. 26, 2024 |
Apr. 28, 2023 |
|
| Business Acquisition [Line Items] | |||
| Contingent consideration | $ 81 | $ 149 | $ 206 |
| Contingent consideration receivable | 58 | ||
| Revenue | $ 181 | 174 | 202 |
| Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] | Other Operating Income (Expense), Net | ||
| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | |||
| Business Acquisition [Line Items] | |||
| Additional funding | $ 391 | ||
| Milestone payments | 1,200 | ||
| Level 3 | Recurring | |||
| Business Acquisition [Line Items] | |||
| Contingent consideration receivable | 13 | 58 | $ 195 |
| Other accrued expenses | |||
| Business Acquisition [Line Items] | |||
| Contingent consideration | 31 | 96 | |
| Other liabilities | |||
| Business Acquisition [Line Items] | |||
| Contingent consideration | $ 50 | $ 53 | |